147 related articles for article (PubMed ID: 18297539)
21. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
[TBL] [Abstract][Full Text] [Related]
22. JAK2V617F Exon-14 Mutation Driven Polycythemia Vera.
Archana A; Ramamoorthy JG; Ranjith Kumar V; Cherian AA; Shapnalakshmi T; Kalyanaprabhakaran B; Akshaykumar R
Indian J Pediatr; 2021 Apr; 88(4):402-403. PubMed ID: 33409949
[No Abstract] [Full Text] [Related]
23. Polycythemia vera in a 2-year-old child with a JAK2 exon 12 deletion.
Dermott SM; Kucine N; Farooqi MS; Li W; Silvey M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28994. PubMed ID: 33661568
[No Abstract] [Full Text] [Related]
24. Quantitative bead-based assay for detection of JAK2 exon 12 mutations.
Shivarov V; Ivanova M; Yaneva S; Petkova N; Hadjiev E; Naumova E
Leuk Lymphoma; 2013 Jun; 54(6):1343-4. PubMed ID: 23121686
[No Abstract] [Full Text] [Related]
25. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
27. Existence of JAK2 mutation 19 years prior to the development of overt polycythemia vera.
Shimazu Y
Hematol Oncol; 2018 Feb; 36(1):355-356. PubMed ID: 28332734
[No Abstract] [Full Text] [Related]
28. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F
Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983
[No Abstract] [Full Text] [Related]
29. Fast and reliable mutation detection of the complete exon 11-15 JAK2 coding region using non-isotopic RNase cleavage assay (NIRCA).
Kambas K; Mitroulis I; Kourtzelis I; Chrysanthopoulou A; Speletas M; Ritis K
Eur J Haematol; 2009 Sep; 83(3):215-9. PubMed ID: 19500139
[TBL] [Abstract][Full Text] [Related]
30. Co-occurrence of JAK2 V617F and an uncommon CALR del (p.K368fs*51) mutation facilitates JAK2/STAT signaling in polycythemia vera.
Xing CY; Li HY; Wu JB; Gao SM
Leuk Lymphoma; 2016 Jul; 57(7):1743-5. PubMed ID: 26701108
[No Abstract] [Full Text] [Related]
31. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
33. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera.
Liu D; Xu Z; Zhang P; Qin T; Li B; Qu S; Pan L; Cai W; Liu J; Wang H; Sun Q; Sun X; Jiao M; Gao Q; Shi Z; Huang H; Huang G; Gale RP; Xiao Z
Blood Cancer J; 2021 Sep; 11(9):154. PubMed ID: 34535626
[No Abstract] [Full Text] [Related]
34. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
Verstovsek S; Silver RT; Cross NC; Tefferi A
Leukemia; 2006 Nov; 20(11):2067. PubMed ID: 16990780
[No Abstract] [Full Text] [Related]
35. [Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
Shen YF; Xia J; Lu MZ; Jiang YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):121-4. PubMed ID: 19236761
[TBL] [Abstract][Full Text] [Related]
36. JAK2 mutations other than V617F: a novel mutation and mini review.
Karow A; Waller C; Reimann C; Niemeyer CM; Kratz CP
Leuk Res; 2008 Feb; 32(2):365-6. PubMed ID: 17466371
[No Abstract] [Full Text] [Related]
37. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
Tondeur S; Paul F; Riou J; Mansier O; Ranta D; Le Clech L; Lippert E; Tavitian S; Chaoui D; Mercier M; De Renzis B; Cottin L; Cassinat B; Chrétien JM; Ianotto JC; Allangba O; Marzac C; Voillat L; Boyer F; Orvain C; Hunault-Berger M; Girodon F; Kiladjian JJ; Ugo V; Luque Paz D
Leukemia; 2021 Mar; 35(3):871-875. PubMed ID: 32694617
[No Abstract] [Full Text] [Related]
38. High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance.
Park CH; Lee KO; Jang JH; Jung CW; Kim JW; Kim SH; Kim HJ
J Clin Pathol; 2016 Aug; 69(8):737-41. PubMed ID: 27198504
[TBL] [Abstract][Full Text] [Related]
39. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
40. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
